trending Market Intelligence /marketintelligence/en/news-insights/trending/tzjytzlljhooi4cvez7ybg2 content esgSubNav
In This List

DiaMedica Therapeutics appoints chief medical officer

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


DiaMedica Therapeutics appoints chief medical officer

Minneapolis-based biotechnology company DiaMedica Therapeutics Inc. appointed Harry Alcorn Jr. as chief medical officer.

Alcorn previously served as chief scientific officer at DaVita Clinical Research. He has also served on the boards of the Association of Clinical Pharmacology Units and MEDTOX Laboratories Inc.

DiaMedica develops treatments for neurological and kidney diseases.